Fabien Pitoiset

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

Michèlle Rosenzwajg, Roberta Lorenzon, P. Cacoub et al. · Annals of the Rheumatic Diseases · 2018 · 402 citations · Full text

Life Sciences, Immunology, Autoimmunity +11

Human and Mouse CD8+CD25+FOXP3+ Regulatory T Cells at Steady State and during Interleukin-2 Therapy

Guillaume Churlaud, Fabien Pitoiset, Fadi Jebbawi et al. · Frontiers in Immunology · 2015 · 205 citations · Full text

Life Sciences, Cell Biology, Immunology +14

Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial

Jens Y. Humrich, P. Cacoub, Michèlle Rosenzwajg et al. · Annals of the Rheumatic Diseases · 2022 · 114 citations

Life Sciences, Immunology, Pharmacotherapy +17

<i>NCKAP1L</i>defects lead to a novel syndrome combining immunodeficiency, lymphoproliferation, and hyperinflammation

Carla N. Castro, Michèlle Rosenzwajg, Raphaël Carapito et al. · The Journal of Experimental Medicine · 2020 · 86 citations · Full text

Life Sciences, Genetics, Immunology +17

Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses

Fabien Pitoiset, Lydie Cassard, Karim El Soufi et al. · Cytometry Part A · 2018 · 75 citations · Full text

Life Sciences, Immunology, Oncology +14